Thromb Haemost 2021; 121(11): 1391-1393
DOI: 10.1055/a-1506-8744
Invited Editorial Focus

Atrial Fibrillation after Cardiac Surgery—To Infinity and Beyond!

Oana Maria Cole
1  Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom
2  Heart and Chest Hospital, Liverpool, United Kingdom
› Author Affiliations

The Prognostic Potential of Atrial Natriuretic Peptide on the Development of Postoperative Atrial Fibrillation after Cardiac Surgery

“It isn't that they can't see the solution. It is that they can't see the problem.”

G.K. Chesterton, “The Scandal of Father Brown” (1935)

New-onset atrial fibrillation (AF) is common after cardiac surgery, with an incidence of 30 to 50%.[1] [2] [3] Patients developing de novo AF after cardiac surgery (AFACS) have a higher risk of developing persistent/long-term AF in the community.[4] An episode of AFACS, even if terminated prior to discharge from hospital, is associated with an increased long-term risk of embolic stroke[5] and higher 10-year all-cause mortality.[6] Considering this, it is then perhaps not surprising that AF has been named as one of the top 10 research priorities for cardiovascular surgery.[7]

Publication History

Received: 06 May 2021

Accepted: 10 May 2021

Publication Date:
11 May 2021 (online)

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany